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A B S T R A C T
Background: Due to the symptoms and the sleep disturbances it causes, Restless Legs Syndrome (RLS)
has a negative impact on quality of life. Measurement of such impact can be performed by means of ques-
tionnaires, such as the Kohnen Restless Legs Syndrome–Quality of Life questionnaire (KRLS-QoL), a speciﬁc
12-item instrument that is self-applied by patients. The present study is aimed at performing a ﬁrst formal
validation study of this instrument.
Methods: Eight hundred ninety-one patients were included for analysis. RLS severity was assessed by
the International Restless Legs Scale (IRLS), Restless Legs Syndrome-6 scales (RLS-6), and Clinical Global
Impression of Severity. In addition the Epworth Sleepiness Scale (ESS) was assessed. Acceptability, di-
mensionality, scaling assumptions, reliability, precision, hypotheses-related validity, and responsiveness
were tested.
Results: There were missing data in 3.58% patients. Floor and ceiling effects were low for the subscales,
global evaluation, and summary index derived from items 1 to 11 after checking that scaling assump-
tions were met. Exploratory parallel factor analysis showed that the KRLS-QoL may be deemed
unidimensional, ie, that all components of the scale are part of one overall general quality of life factor.
Indexes of internal consistency (alpha = 0.88), item-total correlation (rS = 0.32–0.71), item homogeneity
coeﬃcient (0.41), and scale stability (ICC = 0.73) demonstrated a satisfactory reliability of the KRLS-
QoL. Moderate or high correlations were obtained between KRLS-QoL scores and the IRLS, some components
of the RLS-6, inter-KRLS-QoL domains, and global evaluations. Known-groups validity for severity levels
grouping and responsiveness analysis results were satisfactory, the latter showing higher magnitudes
of response for treated than for placebo arms.
Conclusions: The KRLS-QoL was proven an acceptable, reliable, valid, and responsive measure to assess
the impact of the RLS on quality of life.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The Kohnen Restless Legs Syndrome–Quality of Life question-
naire (KRLS-QoL) is a speciﬁc measure for assessment of QoL in
patients with RLS [1] (Table 1). The validation study for the ques-
tionnaire has only previously been published in abstract form [2].
Our study reports its full validation.
The preliminary version of the KRLS_QoL was a 14-item scale
derived from a survey on 721 German patients from self-help groups.
Patients reported openly on consequences of their RLS and the
reports were qualitatively analysed to obtain the core information
for establishing the KQoL-RLS dimensions. A pilot application to 69
RLS patients followed and, subsequently, 12 items were ﬁnally
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Table 1
Kohnen Restless Legs Syndrome–Quality of Life Questionnaire.
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selected for the deﬁnitive version [1]. The KRLS-QoL is a 12-item
self-assessment with questions about physical, mental, social, and
functional impact of RLS, as well as coping behavior. The re-
sponses range from zero (no impairment at all) to 5 (extreme
impairment). Items one to four are focused on “Effects of RLS symp-
toms”; items 5 and 6 on “Disturbed sleep and its effects”; items 7
and 8 refer to “Effects of other features”; and items nine to eleven
compose a “Your way of handling the RLS symptoms” domain. The
item 12 summarizes the perceived impact of the RLS on the quality
of life as a whole. The time frame is “the last 4weeks”. To the purpose
of the present validation study, a composite score was derived from
the KRLS-QoL items one to 11 and was deemed to represent the
impact on QoL due to these questionnaire components. The overall
QoL impairment by RLS assessed by the item 12 was considered
apart, as a global evaluation resulting from a judgment related with
the items included plus other aspects not included in the question-
naire. Furthermore, the addition of the global evaluation to the
summary score resultant from the other items would be partially
redundant.
2. Methods
2.1. Terminology
Health-related quality of life is a patient-reported outcome fre-
quently applied for monitoring the (HRQoL) effect of interventions
in clinical trials and the impact of health status disorders on phys-
ical, mental, and social domains, a multidimensional perspective
derived from theWorld Health Organization deﬁnition of health [3,4].
The term “quality of life” (QoL) is a wider construct than “health-
related quality of life” health being only one of its determinants,
but in the clinical setting both terms are used indistinctly. We will
refer hereafter to health-related quality of life as QoL, understood
as “the perception and evaluation by patients themselves of the
impact that the disease and its consequences have on their life” [5].
HRQoL is usually assessed by means of questionnaires (QoL scales
or measures) that may be generic, both for evaluating the most im-
portant health domains in general population or any condition, and
speciﬁc for populations which assess speciﬁc areas of interest for
certain illnesses, populations or symptoms.
2.2. Patients
The sample for the present study comes from four multicenter,
double-blind, randomized active or placebo-controlled clinical trials
[6–11] and has been previously described [12]. In summary, the in-
clusion criteria for these studies were: both gender patients, aged
18 to 75 (cabergoline trials: CALDIR, CABAS-0067-031: CT.gov Iden-
tiﬁer: NCT00625547; CATOR, CABAS-0067-033: CT.gov Identiﬁer:
NCT00627003) or 18 to 80 (lisuride trials: TULIR 02/01, EudraCT
Number: 2004-001589-42; TULIR 03/01, EudraCT Number: 2005-
003549-16) years, experiencing all four clinical manifestations of
RLS according to the IRLSSG Criteria [13]. Severity of symptoms had
to be at least moderate (IRLS total score at baseline ≥10 for
cabergoline trials; ≥15 for lisuride trials), and a “severity at night”
score of ≥4 (cabergoline trials) in the RLS-6 rating scale. Patients
were either denovo or unsatisﬁed with previous RLS therapy.
Exclusion criteria were: 1) Secondary RLS, iron deﬁciency, or other
clinically relevant concomitant diseases, relevant ﬁndings in ancil-
lary tests, and skin disorders on application area (lisuride patch trials)
Table 1 (continued)
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[8,9]. Uremic RLS patients were allowed in the lisuride studies and
there were seven such patients. 2) Established or suspected hyper-
sensitivity to the tested drug or non-response intolerability to
previous cabergoline or L-dopa therapy (CBG) [6,7]. 3) Concomi-
tant use of drugs with a probable inﬂuence on RLS or sleep structure
were not permitted and had to be discontinued at the start of the
washout period one week before baseline. 4) Previous treatment
with cabergoline [6] or discontinuation of the drug in less than two
months prior to screening [7]. Women of child-bearing potential
had to use a reliable method of contraception. Patients were re-
cruited in outpatient unit of neurological hospitals or in private
neurological sleep laboratories.
2.3. Ethical issues
All four studies were approved by the corresponding Ethics Com-
mittees and patients signed their informed consent before inclusion
in the study.
2.4. Assessments
In addition to the KRLS-QoL the following assessments were
applied: International Restless Legs Scale (IRLS), version for clini-
cal trials [14], Restless Legs Syndrome-6 scales(RLS-6) [12], Epworth
Sleepiness Scale (ESS) [15], and Clinical Global Impression of Se-
verity (CGIS) [16].
The RLS-6 includes six items, each one scoring on a 0–10 scale
from 0 (no symptoms) to 10 (very severe). In addition to ques-
tions about satisfaction with sleep and sleepiness, the scales rate
the severity of RLS for the past week under different circum-
stances and times of day: during the night, during the day while
sitting or lying, and during the day whenmoving around. The RLS-6
scale was not designed to calculate a total score, but to assess the
following speciﬁc domains: 1) Sleep quality (items 1 and 6); 2) RLS
at Nighttime (items 2 and 3); 3) Daytime RLS manifestations during
relaxation (item 4); 4) RLS during activity (item 5) which really is
a control question to differentiate RLS from other disorders.
The IRLS consists of 10 questions rated from 0 to 4. In addition
to the total score, two sub-scores can be obtained: severity and life
impact [17]. The scale is applied under conditions of a face-to-
face interview with the patient where clariﬁcations regarding the
questions can be made to the patient, but the scale can also be self-
completed. It is the most extensively used of the RLS severity scales
in research studies of all types. It has excellent clinimetric proper-
ties and is used as the benchmark outcome measure for treatment
trials in RLS [18].
The ESS and CGIS are generic scales. The ESS is a 8-item scale
to assess excessive daytime somnolence and the CGIS provides a
clinician-based subjective score of severity from 0 (not assessed)
to 7 (among the most extremely ill patients).
2.5. Data analysis
A database for the present study was created from the previ-
ouslymentioned studies [6–11] and submitted to the National Center
of Epidemiology (ISCIII, Madrid, Spain). Descriptive statistics (central
tendency and dispersion, proportions) were applied to the vari-
ables in the study to characterize the sample.
Main variables in the study did not get a normal distribution
(graph plot, Shapiro-Francia test); therefore, non-parametric sta-
tistics were used. In addition to the perceived global impact (item
12), a RLS-related quality of life index based on the scale compo-
nents was derived as arithmetic mean of the item 1 to 11 scores
(KRLS-QoL Index). The following clinimetric attributes were deter-
mined and tested against the corresponding standard values:
Acceptability: Percentage of missing data (standard <10%) [19];
mean and median closeness; range of scores; skewness (between
−1 and +1) [20]; and ﬂoor and ceiling effect (<15%) [21].
Scaling assumptions were explored to determine the appropri-
ateness of summing up the KRLS-QoL items 1 to 11. To this purpose,
the range of means, standard errors of themean, variances, and CI95%
distribution, that must be roughly equivalent, were determined
[22,23].
Dimensionality: It was explored by factor analysis, principal com-
ponent factor. The number of factors was chosen according to the
Kaiser criterion (eigenvalue >1) and scree plot inspection. Bartlett
sphericity index for suitability of the analysis (P < 0.05) and Kaiser-
Meyer-Olkin for sampling adequacy (>0.60) were considered [24].
The ﬁnal number of advised dimensions was explored by Parallel
factor analysis using Unweighted least squares and Exploratory
maximum likelihood methods [25].
Internal consistency: Cronbach’s alpha index, as reliability index
(standard, >0.70) [26]; item-total corrected correlation (standard,
r ≥ 0.30) [19]; and item homogeneity coeﬃcient (standard >0.40)
[27] were determined for items 1 to 11.
Test-retest: A group of 78 patients were considered “stable”
during a homogeneous follow-up period of 90 ± 7 days. The stabil-
ity was determined by a change lower than ±3 points in the IRLS
total score. This limit value was derived from two thresholds in-
dicative of a real change: ½ standard deviation at baseline = 3.17
[28,29] and the standard error of the difference baseline–follow-
up = 3.27 [30]. Weighted kappa with quadratic weighs for items and
intraclass correlation coeﬃcient (ICC, one-way, individual) for the
KRLS-QoL Index were applied. The standard error of measure-
ment, based on the baseline standard deviation and the ICC of the
KRLS-QoL Index, was calculated [31,32].
Hypotheses testing: An a priori close association (r ≥ 0.50) was
expected between the KRLS-QoL and total scores of measures for
RLS severity and impact, whereas moderate (r = 0.35–0.50) or low
correlations (r < 0.35) were expected with other variables in the
study. Internal validity between KRLS-QoL domains would be con-
sidered satisfactory with correlation coeﬃcient values 0.30–0.70
[19,20] and a high correlation was hypothesized between the overall
QoL evaluation (KRLS-QoL Item 12) and the KRLS-QoL Index. Known-
groups validity was determined for severity categories of RLS based
on the IRLS scores, CGIS, and duration of the RLS. For the contin-
uous variables, grouping was carried out according to median and
interquartile range. A signiﬁcant increase of the RLS-6 scores was
expected with increasing RLS severity, whereas the difference for
duration categories could be non-signiﬁcant. Kruskal-Wallis test with
Bonferoni correction was applied for comparisons.
Responsiveness: It was deﬁned as the ability of the RLS-6 to
detect a change. To this purpose, the analysis was carried out on
data from those patients who participated in the placebo-
controlled lisuride clinical trials [8–11] and were followed-up for
a similar period (mean, 90 days; SD, 3.9; range: 83–97). This sample
was composed of 82 patients in the placebo arm and 179 in the
lisuride branch. Patients in the cabergoline trials [6,7] could not
be included as their follow-up was too variable to the purpose of
the analysis (mean, 140.5 days; SD, 81.1; range 7–231). For the
analysed patients, no statistical differences between arms were
found for age, gender, age at onset, and RLS duration at baseline.
The following responsiveness parameters were determined: Rela-
tive change [33], Wilcoxon and Mann-Whitney tests (for intra-
and inter-groups comparisons), effect size, standardized response
mean,and correlation of change between KRLS-QoL index and item
12 with change in RLS severity measures (IRLS, RLS-6, CGIS) were
calculated [34,35].
Analysis were carried out with Stata 13 (Stata Corp.,4905 Lakeway
Drive College Station, Texas 77845 USA) and Factor 9.2 (Univ. Rovira
I Virgili, Tarragona, Spain).
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3. Results
Eight hundred ninety-three patients, mean (±SD) age 58.73 ± 11.46
(range: 21.90–82.34) years, 71.56% women, were included in the
study. Their body mass index was 26.55 ± 4.10 (range: 16.90–
44.98). Historical and evaluative data related with the RLS are shown
in the Table 2.
In the KRLS-QoL there were 1 or 2 missing data in items 5 to
12 in 9 cases and 29 in the item 7, with 861 patients (96.42%) pro-
viding fully completed questionnaires. Imputation by the individual’s
mean [36] was carried out if the proportion of missing data was
≤25%. Two patients were excluded because they had more than 30%
of empty boxes. Therefore, the ﬁnal sample for the KRLS-QoL val-
idation analysis was 891 patients (99.78%). Table 1S (Supplementary
material) shows the results of the Acceptability parameters. The range
of scores for all items was 0–5 and 0.36 to 5 for the KRLS-QoL index.
Data related to scaling assumptions are displayed in the Table 2S
(Supplementary material). The range of values for each tested pa-
rameter was quite narrow, supporting the appropriateness of their
summed scores for obtaining the summary index.
The exploratory factor analysis (Bartlett test, P < 0.00001; Kaiser-
Meyer-Olkin test = 0.90) identiﬁed two factors (explaining 56.85%
of the variance) after orthogonal and promax rotations: Factor 1,
Impaired health by symptoms, included the items 1, 2, 3, 5, 6, 8,
and 12,and Factor 2, Burden of symptoms, included items 7, 10 and
11. Items 4 (Impairment of social activity) and 9 (Burden of relief
methods) did not load clearly on any factor. The parallel factor anal-
ysis advised for considering only 1 dimension in the scale
(Comparative Fit Index = 0.95, 1.32; Goodness of Fit Index = 1.00; Ad-
justed Goodness of Fit Index = 0.99).
Cronbach’s alpha (items 1 to 11) was 0.88, item-total correla-
tion ranged from 0.32 (Item 7) to 0.71 (Items 2 and 5), the inter-
item correlation from 0.11 (item 1 with item 7) to 0.77 (item 5 with
item 6), and the item homogeneity coeﬃcient was 0.41. Concern-
ing the test-retest analysis, kappa values were 0.43 (Item 7) to 0.64
(Item 4) and the ICC for the KRLS-QoL Index, 0.73. For the Item 12,
impairment of QoL by RLS, kappa was 0.56.
Both the KRLS-QoL Index and Domain 5 (Item 12) reached mod-
erate or high correlations with the IRLS total scores and subscores
of severity, moderate or low with the components of the RLS-6 and
CGIS, and weak to negligible with other variables in the study
(Table 3S, Supplementarymaterial). The correlation coeﬃcient values
were lower for the Item 12, except for the variables related with
age (age at study, age at onset) (Table 3S, Supplementary materi-
al). The correlation among KRLS-QoL domains was 0.42–0.74 and
between KRLS-QoL Index and Item 12 was 0.74.
In regard to the known-groups validity, the KRLS-QoL Index and
Item 12 signiﬁcantly increased their scores with increasing RLS se-
verity levels based on the IRLS and CGIS scores, but no with duration
of the disorder (Table 3).
Concerning the responsiveness parameters (Table 4), both KRLS-
QoL Index and Item 12 performed similarly, the latter showing a
trend to reach slightly higher values for most of the parameters than
the KRLS-QoL Index, except for correlations of change. Although a
signiﬁcant placebo effect was present in this study, the responsive-
ness data clearly indicated a higher effect for the group in active
treatment.
4. Discussion
The present study follows the development and initial testing
of the KRLS-QoL, a speciﬁc instrument for QoL assessment in RLS
[1,2,37]. A wide sample of patients with moderate RLS symptoms
on average were evaluated with the tested questionnaire and ad-
ditional recognized measures for RLS.
The results of the present study support the use of the KRLS-
QoL as an acceptable, reliable, valid, and responsive instrument for
assessment of the QoL deterioration caused by the RLS and the results
of the psychometric properties that were explored in the early val-
idation study [2] were overwhelmingly conﬁrmed in this new
analysis.
Missing data were <4% and allowed imputation for obtaining a
ﬁnal full computable sample of 891 patients (99.78%). The itemwith
more missing scores was item 7, related with side effects of med-
ication for RLS. There are several explanations for this ﬁnding, such
as uncertainty to choose a response by those patients without treat-
ment or to identify some symptoms as side effects, etc. A proposal
for decreasing this problem could be to indicate that patients without
treatment should mark “0”. Nonetheless, data quality could be con-
sidered excellent.
Variance, standard error of the mean, and conﬁdence interval
95% provided relatively near values among items 1 to 11 in the scale,
giving support for obtaining an Index representative of the RLS-
related quality of life on the basis of those components. In health-
related quality of life measures with several dimensions, summary
indexes have proved to be helpful reducing proﬁle data to a ﬁgure
Table 2
Descriptive data of the Restless Legs Syndrome and scales in the sample.
Mean SD Min. Max.
RLS duration (a) 13.40 13.24 0 59.70
Duration of treatment (b) 2.69 2.95 0 21.93
Age at onset 45.34 16.21 3.63 78.68
IRLS Total score 27.48 6.34 9 40
IRLS Subscore severity 19.45 3.89 6 24
IRLS Subscore impact 6.36 3.05 0 12
RLS-6 – Sleep quality 12.25 4.36 0 20
RLS-6 – Nighttime 12.82 4.80 1 20
RLS-6 – Daytime 4.90 2.62 0 10
RLS-6 – Mimics 1.59 2.06 0 10
Clinical Global Impression 4.83 0.94 1 7
Epworth Sleepiness Scale 7.85 4.95 0 22
N = 893, except (a), n = 704, and (b), n = 891.
Abbreviations: SD: standard deviation;Min.: Minimum;Max.: Maximum; RLS-6: Rest-
less Legs Scale – 6 items; IRLS: International Restless Legs Scale.
Table 3
Known-groups validity of the Kohnen Restless Legs Syndrome–Quality of Life
questionnaire.
Categories n KRLS-QoL Index KRLS-QoL Item 12
Mean SD Mean SD
RLS Duration (years)*
<3.30 220 2.47 0.91 3.22 1.10
3.30–8.86 224 2.45 0.90 3.17 1.03
8.87–19.77 222 2.48 0.92 3.15 1.11
≥19.78 225 2.72 0.91 3.23 1.21
P – 0.003 0.56
IRLS score
<23 205 1.79 0.76 2.31 1.13
23–27 218 2.16 0.68 2.87 1.00
28–31 198 2.62 0.70 3.42 0.79
≥32 270 3.33 0.64 3.95 0.76
P – 0.0001 0.0001
CGI-Severity
Normal (1) 3 1.58 1.23 1.67 2.08
Mild (2, 3) 49 2.09 0.96 2.65 1.13
Moderate (4) 267 2.13 0.76 2.82 1.07
Severe (5) 351 2.53 0.89 3.19 1.10
Very severe (6, 7) 221 3.12 0.77 3.80 0.87
P – 0.0001 0.0001
(P) Kruskal-Wallis test. Signiﬁcance after Bonferroni correction, P < 0.0083.
Abbreviations: SD: Standard deviation; CGI: Clinical Global Impression; RLS-6: Rest-
less Legs Scale – 6 items; IRLS: International Restless Legs Scale; RLS: Restless Legs
Syndrome.
* Categories according to interquartile range.
14 R. Kohnen et al. / Sleep Medicine 24 (2016) 10–17
representative of the impact by the disorder [38–40]. Such summary
score is not equivalent to the single-item overall quality of life ap-
praisal, a direct judgment including those aspects considered into
the proﬁle plus others [41–43].
The KRLS-QoL domains and Index showed acceptability results
into the range of standard values, with close median to mean values,
absence of signiﬁcant ﬂoor or ceiling effects, and items covering the
full range of potential scores without skewness (except a margin-
al skewness for item 7). In summary, the parameters referred to
KRLS-QoL acceptability are deemed satisfactory.
As in the early validation report [2], two factors (with similar
composition) and almost equivalent explained variance (56.67% vs.
56.85%) were found, although the Parallel analysis showed that the
scale can be considered unidimensional and, therefore, with all items
grouped around a single construct, namely QoL. Cronbach’s alpha
valuewas also almost equivalent to the previous study (0.89 vs. 0.88),
and indicative of a satisfactory internal consistency. Other param-
eters of reliability, including item-total correlation and homogeneity
index resulted over the adequacy threshold for these scale prop-
erties. The stability of KRLS-QoL scores was moderate to substantial
for the items and acceptable for the Index. It is relevant to empha-
size that the considered re-test was performed three months after
the ﬁrst application, a long period in comparison with the usual two
to four weeks span. This fact probably has allowed some bias (for
example, regression to the mean, variation in the reaction, etc.) that
decreased the reproducibility of the scores.
Concerning the convergent validity of the scale, high correla-
tions were found between KRLS-QoL index and Item 12 and the IRLS
(total and impact scales, mainly) and RLS-6 Sleep quality domain.
The correlation between other KRLS-QoL components and these
scales and CGIS ranged from weak to strong (Table S3, Supplemen-
tary material). Again, the most relevant results were almost
coincident with the previous validation study [2] and, a as whole,
performed as hypothesized. To be highlighted of note, a weak to
negligible association was found with age, duration of RLS, and ESS.
The internal validity (inter-domains correlations) was into the
standard values and the correlation between KRLS-QoL index and
global QoL evaluation (Domain 5. Item 12) was 0.74, demonstrat-
ing close association but no equivalence of both estimations [41–43],
a fact observed in similar circumstances with measures for other
constructs [44–46]. Therefore, the RLS-QoL allows one to assess the
impact on QoL of several RLS speciﬁc aspects as well as a global ap-
praisal directly estimated by the patient.
Known-groups validity analysis, as expected, showed signiﬁ-
cant higher impact on the QoL for increasing levels of severity
according the IRLS and CGIS (Table 3). The association between RLS
duration categories and RLS-QoL scores was lower, reaching non-
signiﬁcant values for the Domain 5. Item 12.
A remarkable placebo effect has been previously observed in RLS
studies, both with the IRLS and RLS-6 in this series [12] and also
is found with the KRLS-QoL. Nonetheless, the responsiveness pa-
rameters of this scale showed a considerable decrease in scores,
relative change, signiﬁcant change between baseline and follow-
up evaluations (both intra- e inter-groups), for placebo and lisuride
groups, with higher magnitudes for the latter. Effect size and stan-
dardized response mean resulted large for lisuride and moderate,
as a whole, for placebo. The correlations of change were high with
the IRLS for both groups and moderate to high with RLS-6 Sleep
quality and Nighttimemanifestations (Table 4), and constantly higher
for the lisuride group. Differences between values with KRLS-QoL
Index and Domain 5. Item 12 were marginal. Therefore, KRLS-QoL
is deemed a responsive measure with two useful summary ﬁgures.
A relevant limitation of the study is related to the origin of the
data, as patients were selected for clinical trials and the study was
not designed for validation of a health measure. Nonetheless, the
sample size, the high quality of the data and the implementation
of a therapeutic intervention that allowed testing the question-
naire responsiveness provide strength to the ﬁndings.
The KRLS-QoL is one of the three questionnaires for measuring
the impact of RLS on the patients QoL identiﬁed by the Movement
Disorder Society Task Force (MDS-TF) that carried out a systemat-
ic review of this kind of instruments [37]. The Abetz RLS-QoL is a
18-item questionnaire providing four-week time frame assess-
ment. A summary score derived of 10 of the 18 items is obtained
Table 4
Kohnen Restless Legs Syndrome–Quality of Life questionnaire responsiveness data.
KRLS-QoL Index KRLS-QoL Item 12
Mean ± SD Placebo Baseline 2.53 ± 0.83 3.13 ± 1.00
Follow-up 1.92 ± 1.17 2.27 ± 1.44
Difference 0.61 ± 1.02 0.87 ± 1.37
Lisuride Baseline 2.64 ± 0.83 3.35 ± 0.98
Follow-up 1.54 ± 1.15 1.84 ± 1.44
Difference 1.10 ± 1.11 1.52 ± 1.50
Relative change (5)
Placebo −24.11 −24.48
Lisuride −41.62 −45.10
Difference intra-group*
Placebo (z = 1.84) P < 0.0001 (z = 4.83) P < 0.0001
Lisuride (z = 9.69) P < 0.0001 (z = 9.83) P < 0.0001
Difference inter-groups† (z = −3.58) P = 0.0003 (z = −3.34) P = 0.0008
Effect size
Placebo 0.73 0.87
Lisuride 1.34 1.55
Standardized response mean
Placebo 0.60 0.64
Lisuride 1.00 1.01
Correlation of change (Placebo | Lisuride)
International Restless Legs Scale 0.62 | 0.74 0.53 | 0.70
RLS-6 Sleep quality 0.42 | 0.65 0.42 | 0.56
RLS-6 Nighttime manifestations 0.54 | 0.68 0.55 | 0.65
RLS-6 Daytime manifestations 0.43 | 0.60 0.36 | 0.54
RLS-6 Mimics 0.16 | 0.35 0.07 | 0.35
Clinical Global Impression of Severity 0.55 | 0.62 0.43 | 0.53
* Wilcoxon test.
† Mann-Whitney test.
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with the other items, some scored as continuous and others as cat-
egorical variables, being excluded of this score by different reasons
[47]. It has shown excellent attributes (acceptability, reliability, and
responsiveness) and met the MDS-TF criteria to be “Recommended”
as a valid instrument for assessment of QoL in RLS. The Restless Legs
Syndrome Quality of Life Instrument (RLS-QLI) is a 17-item ques-
tionnaire with four scales identiﬁed through factor analysis: Daily
Function, Social Function, Sleep Quality, and Emotional Well-
Being [48]. It evaluates the RLS impact on the past 30 days and
although the tested clinimetric properties resulted satisfactory, there
was not information about the responsiveness and a diagnosis of
true RLS in the subjects participating in the validation study could
not be assured. Therefore, the RLS-QLI was qualiﬁed “Suggested”
by the MDS-TF. The KRLS-QoL was classiﬁed as suggested on the
basis of preliminary data of validity [2], but there were not data on
stability and responsiveness reaching a recommendation of “Sug-
gested” [37]. The present study completes this gap andwould allocate
this questionnaire as a valid, “Recommended” alternative measure
for assessment of QoL in RLS.
Overall the Abetz RLS-QOL, the RLS-QLI and the KRLS-QOL have
comparable psychometric properties and are good measures of RLS
QOL under baseline conditions as can be seen by a comparison of
all three scales in Table 5. However, only the Abetz-QOL and the
KRLS-QOL have been shown to be responsive to change under ther-
apeutic conditions (Table 5).
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